Cybin Inc. (CYBN): Price and Financial Metrics
GET POWR RATINGS... FREE!
CYBN Stock Price Chart Interactive Chart >
CYBN Price/Volume Stats
| Current price | $0.39 | 52-week high | $1.16 |
| Prev. close | $0.39 | 52-week low | $0.26 |
| Day low | $0.38 | Volume | 1,237,460 |
| Day high | $0.40 | Avg. volume | 1,933,521 |
| 50-day MA | $0.38 | Dividend yield | N/A |
| 200-day MA | $0.57 | Market Cap | 72.12M |
Cybin Inc. (CYBN) Company Bio
Cybin, Inc. is a biotechnology company that focuses on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. It operates through the following segments: Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Latest CYBN News From Around the Web
Below are the latest news stories about CYBIN INC that investors may wish to consider to help them evaluate CYBN as an investment opportunity.
Weekly Roundup on the Cannabis Sector & Psychedelic SectorKey Takeaways; Cannabis Sector 22nd Century announced partnerships with Core-Mark and Eby-Brown, two of the largest U.S. convenience store distributors. Scotts Miracle-Gro announced timing for Q1 financial results and conference call. Tilray’s revenue declines as net losses increase; if cannabis sales continue to be slow, the company may switch to fruit and beer sales. Key […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive. |
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the BrainTORONTO, January 18, 2023--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel ("Kernel"), evaluating Kernel’s Flow® wearable technology to measure ketamine's psychedelic effect on cerebral cortex hemodynamics. Results from this Cybin-sponsored study are intended to inform the future pathwa |
Trippy Trading: Top Psychedelic Stocks For 2023When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie... |
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004TORONTO, January 12, 2023--Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics® today announced that it has selected Generalized Anxiety Disorder ("GAD") with or without major depressive disorder ("MDD") as the target indication for its proprietary deuterated N, N-dimethyltryptamine ("DMT") molecule, CYB004. |
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development ProgramsTORONTO, January 08, 2023--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today outlined its upcoming priorities and near-term milestones that support the development of its CYB003 and CYB004 clinical programs aimed at addressing multiple mental health conditions. |
CYBN Price Returns
| 1-mo | 31.27% |
| 3-mo | -15.22% |
| 6-mo | -37.10% |
| 1-year | -62.86% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 31.27% |
| 2022 | -75.24% |
| 2021 | -19.46% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...